TME Pharma N.V. (ALTME.PA)

EUR 0.06

(1.1%)

Long Term Debt Summary of TME Pharma N.V.

  • TME Pharma N.V.'s latest annual long term debt in 2023 was - EUR , down -100.0% from previous year.
  • TME Pharma N.V.'s latest quarterly long term debt in 2024 Q2 was - EUR , down 0.0% from previous quarter.
  • TME Pharma N.V. reported annual long term debt of 67 Thousand EUR in 2022, down 0.0% from previous year.
  • TME Pharma N.V. reported annual long term debt of - EUR in 2021, down -100.0% from previous year.
  • TME Pharma N.V. reported quarterly long term debt of - EUR for 2023 FY, down -100.0% from previous quarter.
  • TME Pharma N.V. reported quarterly long term debt of - EUR for 2023 Q4, down 0.0% from previous quarter.

Annual Long Term Debt Chart of TME Pharma N.V. (2023 - 2014)

Historical Annual Long Term Debt of TME Pharma N.V. (2023 - 2014)

Year Long Term Debt Long Term Debt Growth
2023 - EUR -100.0%
2022 67 Thousand EUR 0.0%
2021 - EUR -100.0%
2020 21 Thousand EUR -69.57%
2019 69 Thousand EUR -20.69%
2018 87 Thousand EUR -90.67%
2017 932 Thousand EUR 0.0%
2016 - EUR -100.0%
2015 6.28 Million EUR 51.47%
2014 4.15 Million EUR 0.0%

Peer Long Term Debt Comparison of TME Pharma N.V.

Name Long Term Debt Long Term Debt Difference
ABIONYX Pharma SA 1.1 Million EUR 100.0%
ABIVAX Société Anonyme 44.69 Million EUR 100.0%
Adocia SA 4.54 Million EUR 100.0%
Aelis Farma SA 2.04 Million EUR 100.0%
Biophytis S.A. 3.11 Million EUR 100.0%
Advicenne S.A. 15.89 Million EUR 100.0%
genOway Société anonyme 5.51 Million EUR 100.0%
IntegraGen SA 642.28 Thousand EUR 100.0%
Medesis Pharma S.A. 1.2 Million EUR 100.0%
Neovacs S.A. 650 Thousand EUR 100.0%
NFL Biosciences SA 39.2 Thousand EUR 100.0%
Plant Advanced Technologies SA 4.35 Million EUR 100.0%
Quantum Genomics Société Anonyme 1.96 Million EUR 100.0%
Sensorion SA 1.24 Million EUR 100.0%
Theranexus Société Anonyme 2.46 Million EUR 100.0%
Valbiotis SA 3.89 Million EUR 100.0%
TheraVet SA 1 Million EUR 100.0%
Valerio Therapeutics Société anonyme 6.9 Million EUR 100.0%
argenx SE 15.35 Million EUR 100.0%
BioSenic S.A. 15.57 Million EUR 100.0%
Celyad Oncology SA 902 Thousand EUR 100.0%
DBV Technologies S.A. 4.52 Million USD 100.0%
Galapagos NV 4.94 Million EUR 100.0%
Genfit S.A. 62.25 Million EUR 100.0%
GeNeuro SA 6.49 Million EUR 100.0%
Hyloris Pharmaceuticals SA 344 Thousand EUR 100.0%
Innate Pharma S.A. 30.6 Million EUR 100.0%
Inventiva S.A. 25.61 Million EUR 100.0%
MaaT Pharma SA 5.42 Million EUR 100.0%
MedinCell S.A. 52.8 Million EUR 100.0%
Nanobiotix S.A. 41.66 Million EUR 100.0%
Onward Medical N.V. 16.3 Million EUR 100.0%
Oryzon Genomics S.A. 3.45 Million EUR 100.0%
OSE Immunotherapeutics SA 35.5 Million EUR 100.0%
Oxurion NV 117 Thousand EUR 100.0%
Pharming Group N.V. 123.65 Million EUR 100.0%
Poxel S.A. 40.14 Million EUR 100.0%
GenSight Biologics S.A. 1.04 Million EUR 100.0%
Transgene SA 17 Thousand EUR 100.0%
Financière de Tubize SA - EUR NaN%
UCB SA 2.87 Billion EUR 100.0%
Valneva SE 132.76 Million EUR 100.0%
Vivoryon Therapeutics N.V. - EUR NaN%